Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to a Phase 4 clinical trial comparison between two over-the-counter lubricant eye drop products, **Optive** and **Systane**, conducted by Innovative Medical for the treatment of dry eye syndrome. Optive, developed by Allergan, contains carboxymethylcellulose sodium and glycerin as its active ingredients. Systane, developed by Alcon, contains polyethylene glycol and propylene glycol. Both products are artificial tear formulations that function as small molecule lubricants to mechanically supplement the tear film, providing hydration and protection to the ocular surface. The trial specifically evaluated the subjective duration of action and frequency of use of these two products when used concomitantly with topical cyclosporine (Restasis) in patients with mild to moderate dry eye disease. Neither product targets a specific biological receptor; instead, they work mechanically to relieve symptoms such as dryness, irritation, and discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Optive and Systane.